Khashayarsha Khazaie
Professor and Consultant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Early-onset colorectal cancer (EOCRC) in people < 50 years of age has been rising globally, yet its causes remain unknown. Emerging evidence suggests that environmental factors, including exposure to micro-and nanoplastics (MNPs), may contribute to colorectal carcinogenesis. MNPs can enter the gastrointestinal tract through ingestion, translocate across the epithelial barrier via endocytosis or paracellular pathways, and interact directly with epithelial and immune cells. Once internalized, they may generate events associated with tumor initiation including oxidative stress, disruption of membrane integrity, pro-inflammatory signaling, and disruption of genomic and epigenomic stability. Patient-derived colorectal organoids offer a physiologically relevant and scalable 3D model that closely mimics the cellular architecture and genetic landscape of primary tumors. We highlight how organoid models can be leveraged to study the impact of MNPs on the key processes of inflammation, DNA damage, senescence, and epigenetic modifications. Furthermore, we discuss the application of organoid-based systems to model EOCRC driven by environmental exposures, including the integration of organoid platforms with high-throughput assays, omics profiling, and microfluidics to better capture MNP-induced pathogenic mechanisms. Altogether, colorectal organoids provide a powerful bridge between environmental plastic exposure and EOCRC etiology, offering a tractable platform to identify mechanistic pathways and potential biomarkers of early disease.
Year:
2025
Purpose: Intratumoral injection of Clostridium novyi -nontoxic ( C. novyi -NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi -NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi -NT injection (day 8) across four dose cohorts (3 × 10 4 to 100 × 10 4 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 10 4 C. novyi -NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi -NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Year:
2025
Supplementary Table S1. Planned dose levels of Clostridium novyi-NT given intratumorally in combination with the PD-1 inhibitor, pembrolizumab at 200mg intravenously every 3 weeks (cycle = 21 days).
Year:
2025
Oral commensals such as Parvimonas micra are increasingly implicated in sporadic colorectal cancer (CRC). Several findings support an emerging notion that alterations in host DNA methylation constitute a mechanism by which P. micra adapts to the host microenvironment and contributes to pathogenic processes. However, multiple limitations hinder definitive conclusions, including the correlative nature of the human studies and the absence of human microbiota in mouse models. Here, we investigated how a complex human microbiome influences the adaptation and oncogenic potential of P. micra in a spontaneous mouse model of polyposis. Adult mice, following antibiotic conditioning, received fecal microbiota transplants (FMT) from a healthy human donor, with or without supplementation of P. micra. P. micra caused significant reshaping of the gut microbial community and altered co-occurrence network structures, which however largely recovered within 21 days post FMT. Despite the transient nature of these changes, P. micra caused a marked increase in both the number and invasive potential of intestinal polyps. Epigenomic profiling of polyp crypts revealed global DNA hypomethylation alongside gene-specific hypermethylation, accompanied by transcriptional changes in key oncogenic pathways. Affected pathways included Wnt signaling, epithelial-to-mesenchymal transition, circadian rhythm regulation, and host–microbe interactions. These findings demonstrate that P. micra exerts a profound influence on microbial ecology, host epigenetic programming, and tumorigenesis in a genetically predisposed host, highlighting its role as a microbial driver of intestinal carcinogenesis.
Year:
2025
Collaborators (13)
Kanwal Raghav
Professor
The University of Texas MD Anderson Cancer Center
Michael Sadowsky
University of Minnesota
Aung Naing
The University of Texas MD Anderson Cancer Center
Lisa Boardman
Professor of Medicine
Mayo Clinic
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Anthony P. Conley
Associate Professor
The University of Texas MD Anderson Cancer Center
Christopher Staley
Faculty, Associate Professor
University of Minnesota
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
Siqing Fu
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Rodabe N. Amaria
Assistant Professor
The University of Texas MD Anderson Cancer Center
Fotini Gounari
Professor
Mayo Clinic
Senthil Damodaran
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.